Breast cancer is the most common type of cancer among women in Norway. about 3,500 new cases are diagnosed each year. Screening with mammography can detect breast cancer in an early stage. The goal of screening is to reduce breast cancer deaths and to offer women less aggressive treatment; however, screening also carries some risks.
In Norway, women aged 50-69 years old are invited to BreastScreen Norway. These women need information on both the benefits and harms of screening to make an informed choice whether to participate.
The principle behind mammography screening is to examine many otherwise healthy women in order to identify the few who have breast cancer. It is important to minimize the risks associated with screening, and avoid unneccesary treatment.
BreastScreen Norway works continuously to minimize the risks of mammographic screening, including the risk of overdiagnosis or underdiagnosis of breast cancer, among others.
Overdiagnoses occurs when screening detects small, slow-growing tumours that would never have caused symptoms or been detected if a woman hadn´t been screened. It is currently not possible to determine which specific tumours are overdiagnosed. Because of this, overdiagnosis can lead to overtreatment. How often overdiagnosis occurs is highly discussed because there is no agreement on how to best estimate it. Some studies estimate that mammographic screening leads to a very low rate of overdiagnosis. Others have estimated relatively high rates of overdiagnosis.
Underdiagnosis can occur when a breast tumour is overlooked. These tumours can later be detected between two screening examinations because of symptoms. Tumours detected between two screening examinations often have a worse prognosis than breast cancers that are detected as a result of screening. Only a small percentage of breast cancer cases in a screening program are underdiagnosed. This means that many mammography images are needed to perform a robust study. Obtaining these data is challenging.
Awareness and knowledge about breast cancer, particularly overdiagnosis and underdiagnosis, can be important for women when they decide whether to participate in BreastScreen Norway.
Through this project, we will describe tumour characteristics and survival among women with potentially overdiagnosed or underiagnosed cancers in BreastScreen Norway. Additionally, we will estimate the rate of overdiagnosis in the program, using individual-level data that includes information on socioeconomic factors, to obtain a more precise estimate of the rate of overdiagnosis in Norway.
We will also study women´s awareness and knowledge about breast cancer, including risks associated with screening. The aim of this is to determine whether women invited to participate in screening have adequate knowledge to make an informed choice whether to participate in BreastScreen Norway.
Study 1: Describe tumour characteristics and survival for potentially overdiagnosed or underdiagnosed interval and screen-detected breast cancers. Retrospective cohort study, based on individual-level data. Published:Tsuruda KM et al: Survival among women diagnosed with screen-detected or interval breast cancer classified as true, minimal signs, or missed through an informed radiological review. Eur Radiol. 2020. [Epub ahead of print] doi: 10.1007/s00330-020-07340-4
Study 2: Estimate the rate of overdiagnosis in the screening program using individual-level data, after adjustment for socioeconomic factors. This study will give new knowledge about how socioeconomic factors can affect rates of overdiagnosis. Retrospective cohort study, based on individual-level data. In progress.
Study 3: To describe Norwegian women’s awareness and knowledge about under- and overdiagnosis and breast screening in general. Cross-sectional study based on an online questionnaire sent to women aged 50-69 in Norway. In progress.
Additional study, published: Tsuruda KM, Hofvind S, Akslen LA, Hoff SR, Veierød MB. Terminal digit preference: a source of measurement error in breast cancer diameter reporting. Acta Oncol. 2020;59(3):260-7.
The PhD candidate is Kaitlyn Tsuruda, MSc, Cancer Registry of Norway.
The primary investigator and supervisor of this project is Solveig Hofvind, head of the mammography section at the Cancer Registry of Norway, and professor of radiography at Oslo Metropolitan University.
Marit Veierød, professor in biostatistics at the University of Oslo, is the co-supervisor.
External collaborators include:
- Lars A Akslen, Centre for Cancer Biomarkers CCBIO, University of Bergen and Haukeland University Hospital
- Sameer Bhargava, Vestre Viken Hospital Trust
- Gunvor G. Wåde, Oslo Metropolitan University
- Nehmat Houssami, University of Sydney (Australia)
- Tone Hovda, Vestre Viken Hospital Trust
- Solveig Roth Hoff, Ålesund Hospital